Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]APG-2575 in Healthy Subjects
NCT05517616Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lisaftoclax in hematologic malignancy, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 1 more, sponsored by Ascentage Pharma. Primary endpoints: Radioactivity concentration of each blood and plasma sample, Radioactivity concentration in each urine and feces sample and 1 more. Started Sep 2022; status: completed.
02
Drugs
lisaftoclax
03
Conditions
hematologic malignancychronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05517616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517616.